# Lutris Pharma

> Clinical-stage biopharma developing LUT014, a topical B-RAF inhibitor that mitigates dermal toxicities (acneiform rash) caused by EGFR inhibitors, RAS inhibnitors and other MAPK-pathway inhibitors.

## Pages

- [Home](/): Overview of Lutris Pharma and the LUT014 program.
- [Technology — Mechanism of Action](/technology): How LUT014 leverages the paradoxical effect of B-RAF inhibition in the MAPK pathway.
- [Scientific Publications](/technology/publications): Peer-reviewed publications on LUT014 across acneiform rash, wound healing, and radiation dermatitis.
- [Clinical Trials](/clinical-trials): Phase 1 and Phase 2 clinical development of LUT014.
- [Team](/team): Leadership team.
- [Board of Directors](/team/board): Board members.
- [Scientific Advisory Board](/team/sab): Scientific advisors.
- [Investors](/investors): Lead investors backing Lutris Pharma.
- [News & Updates](/investor-relations): Press releases and announcements.
- [FAQ](/faq): Frequently asked questions about the company and LUT014.
- [Contact](/contact): Get in touch about partnership or clinical inquiries.